Literature DB >> 17074669

Tumor metabolism: new opportunities for cancer therapy.

Isabel Mérida1, Antonia Avila-Flores.   

Abstract

Mammalian cells depend on extracellular input for the regulation of growth, proliferation and survival. Cancer cells evade these requirements, and are able to take up nutrients in a cell-autonomous fashion, which allows continuous growth and proliferation. To fulfill the high bioenergetic demands imposed by transformation, tumors must develop alternative mechanisms of energy production. Accordingly, the biochemical signature of cancer cells involves a shift to aerobic glycolysis, also known as the "Warburg effect". This property of cancer cells has resulted of great utility in modern medicine for detection of early tumors by positron-emission scanning. Nonetheless, the underlying mechanisms and contribution of the Warburg effect to the malignant phenotype have remained obscure. Thanks to recent advances in cancer research, we are beginning to understand the link between cancer genetics and the abnormal use of glucose by tumors. A new scenario is thus emerging, in which bioenergetics would contribute to and sustain malignant transformation. These findings are not only important for a better understanding of tumorigenesis; tumor reliance on glycolysis can be exploited in the search for novel, more potent therapeutic approaches to cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17074669     DOI: 10.1007/s12094-006-0117-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  27 in total

Review 1.  The IGF-1 receptor in cancer biology.

Authors:  Renato Baserga; Francesca Peruzzi; Krysztof Reiss
Journal:  Int J Cancer       Date:  2003-12-20       Impact factor: 7.396

2.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

Review 3.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Authors:  Jeffrey A Engelman; Ji Luo; Lewis C Cantley
Journal:  Nat Rev Genet       Date:  2006-08       Impact factor: 53.242

Review 4.  Current development of mTOR inhibitors as anticancer agents.

Authors:  Sandrine Faivre; Guido Kroemer; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

5.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.

Authors:  Russell G Jones; David R Plas; Sara Kubek; Monica Buzzai; James Mu; Yang Xu; Morris J Birnbaum; Craig B Thompson
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

Review 6.  Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology.

Authors:  G L Semenza
Journal:  Trends Mol Med       Date:  2001-08       Impact factor: 11.951

7.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer.

Authors:  Ian P M Tomlinson; N Afrina Alam; Andrew J Rowan; Ella Barclay; Emma E M Jaeger; David Kelsell; Irene Leigh; Patricia Gorman; Hanan Lamlum; Shamima Rahman; Rebecca R Roylance; Simon Olpin; Stephen Bevan; Karen Barker; Nicholas Hearle; Richard S Houlston; Maija Kiuru; Rainer Lehtonen; Auli Karhu; Susa Vilkki; Päivi Laiho; Carita Eklund; Outi Vierimaa; Kristiina Aittomäki; Marja Hietala; Pertti Sistonen; Anders Paetau; Reijo Salovaara; Riitta Herva; Virpi Launonen; Lauri A Aaltonen
Journal:  Nat Genet       Date:  2002-02-25       Impact factor: 38.330

8.  Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome.

Authors:  Michael N Corradetti; Ken Inoki; Nabeel Bardeesy; Ronald A DePinho; Kun-Liang Guan
Journal:  Genes Dev       Date:  2004-07-01       Impact factor: 11.361

9.  The crystal structure of a multifunctional protein: phosphoglucose isomerase/autocrine motility factor/neuroleukin.

Authors:  Y J Sun; C C Chou; W S Chen; R T Wu; M Meng; C D Hsiao
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

10.  Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.

Authors:  James Brugarolas; Kui Lei; Rebecca L Hurley; Brendan D Manning; Jan H Reiling; Ernst Hafen; Lee A Witters; Leif W Ellisen; William G Kaelin
Journal:  Genes Dev       Date:  2004-11-15       Impact factor: 11.361

View more
  20 in total

1.  Progressing Toward a Cohesive Pediatric 18F-FDG PET/MR Protocol: Is Administration of Gadolinium Chelates Necessary?

Authors:  Christopher Klenk; Rakhee Gawande; Vy Thao Tran; Jennifer Trinh Leung; Kevin Chi; Daniel Owen; Sandra Luna-Fineman; Kathleen M Sakamoto; Alex McMillan; Andy Quon; Heike E Daldrup-Link
Journal:  J Nucl Med       Date:  2015-10-15       Impact factor: 10.057

2.  Role of cellular bioenergetics in smooth muscle cell proliferation induced by platelet-derived growth factor.

Authors:  Jessica Perez; Bradford G Hill; Gloria A Benavides; Brian P Dranka; Victor M Darley-Usmar
Journal:  Biochem J       Date:  2010-05-13       Impact factor: 3.857

3.  Tumor microsomal metabolism of the food toxicant, benzo(a)pyrene, in ApcMin mouse model of colon cancer.

Authors:  Deacqunita L Diggs; Kelly L Harris; Perumalla V Rekhadevi; Aramandla Ramesh
Journal:  Tumour Biol       Date:  2012-03-20

4.  Biological correlates of tumor perfusion and its heterogeneity in newly diagnosed breast cancer using dynamic first-pass 18F-FDG PET/CT.

Authors:  Neree Payan; Benoit Presles; François Brunotte; Charles Coutant; Isabelle Desmoulins; Jean-Marc Vrigneaud; Alexandre Cochet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-08       Impact factor: 9.236

5.  Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe.

Authors:  Erwin Garcia; Chris Andrews; Jia Hua; Hyung L Kim; Dinesh K Sukumaran; Thomas Szyperski; Kunle Odunsi
Journal:  J Proteome Res       Date:  2011-02-22       Impact factor: 4.466

Review 6.  Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.

Authors:  Liliana E Lucca; David A Hafler
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 7.  Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen.

Authors:  Peter L Pedersen
Journal:  J Bioenerg Biomembr       Date:  2007-06       Impact factor: 2.945

8.  Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.

Authors:  A Vazquez-Martin; R Colomer; J Brunet; R Lupu; J A Menendez
Journal:  Cell Prolif       Date:  2008-02       Impact factor: 6.831

9.  Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers.

Authors:  Y Liu; G L Borchert; A Surazynski; J M Phang
Journal:  Oncogene       Date:  2008-09-15       Impact factor: 9.867

10.  Proline oxidase functions as a mitochondrial tumor suppressor in human cancers.

Authors:  Yongmin Liu; Gregory L Borchert; Steven P Donald; Bhalchandra A Diwan; Miriam Anver; James M Phang
Journal:  Cancer Res       Date:  2009-08-04       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.